Isomorphic Labs vs CropX

Side-by-side comparison of AI visibility scores, market position, and capabilities

CropX leads in AI visibility (44 vs 34)
Isomorphic Labs logo

Isomorphic Labs

EmergingHealthcare & Life Sciences

AI Drug Discovery

Alphabet/DeepMind drug discovery spinoff raised $600M from Thrive Capital; Drug Design Engine doubled AlphaFold3 accuracy for molecular design; partnering with major pharma; preparing first clinical trials from AI-directed drug pipeline across multiple therapeutic areas.

AI VisibilityBeta
Overall Score
D34
Category Rank
#6 of 7
AI Consensus
60%
Trend
up
Per Platform
ChatGPT
45
Perplexity
33
Gemini
31

About

Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical candidate selection. Founded in 2021 under CEO Demis Hassabis's vision of using AI to accelerate medicine, Isomorphic operates with the scientific resources and computational infrastructure of DeepMind while functioning as a standalone drug discovery organization. The company's founding mission is to use AI not merely as a tool to assist drug hunters, but as the primary engine of drug design — replacing the slow, expensive, and largely empirical process of traditional medicinal chemistry with AI-directed molecular engineering.\n\nIsomorphic's core platform is the Drug Design Engine, a proprietary AI system built on top of AlphaFold architecture. The Drug Design Engine has achieved landmark performance results, reportedly doubling the accuracy of AlphaFold3 at predicting how small molecules bind to their protein targets — the fundamental problem in structure-based drug design. This capability enables Isomorphic to computationally design molecules predicted to bind their targets with far greater precision than conventional methods, potentially eliminating many of the expensive iterative cycles that make drug development so slow. The company has also established major pharma partnerships with Eli Lilly and Novartis to co-develop drug candidates across multiple therapeutic areas.\n\nIsomorphic raised $600M from Thrive Capital in 2024–2025, bringing substantial private capital alongside its Alphabet backing to accelerate pipeline development. As of 2026, the company is preparing for its first clinical trials — a critical milestone that will test whether its computational drug design predictions translate into human efficacy. With AlphaFold-derived technology at its core, partnerships with two of the world's largest pharmaceutical companies, and over half a billion in funding, Isomorphic Labs represents the most credentialed and well-resourced pure-play AI drug discovery company in existence.

Full profile
CropX logo

CropX

ChallengerAgriculture

Soil Sensing

$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model

AI VisibilityBeta
Overall Score
C44
Category Rank
#1 of 1
AI Consensus
55%
Trend
stable
Per Platform
ChatGPT
45
Perplexity
35
Gemini
53

About

CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.

Full profile

AI Visibility Head-to-Head

34
Overall Score
44
#6
Category Rank
#1
60
AI Consensus
55
up
Trend
stable
45
ChatGPT
45
33
Perplexity
35
31
Gemini
53
29
Claude
52
30
Grok
42

Capabilities & Ecosystem

Capabilities

Only Isomorphic Labs
AI Drug Discovery
Only CropX
Soil Sensing

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.